We describe here tha current state of progress toward gene-directed antisense-based cancer therapy targeting BCR/ABL, oncogene, primarily from the viewpoint of initial proof-of-concepts studies in animal models of human leukemias and phase I clinical investigations.
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.